Patents by Inventor Janet L. Rideout
Janet L. Rideout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5900407Abstract: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5'-triphosphate ?UTP!, dinucleotides, cytidine 5'-triphosphate ?CTP!, adenosine 5'-triphosphate ?ATP!, or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: February 6, 1997Date of Patent: May 4, 1999Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Patent number: 5837861Abstract: The present invention encompasses structures of the formula ##STR1## wherein: X is oxygen, methylene, or difluoromethylene;n=0 or 1;m=0 or 1;n+m=0, 1 or 2; andB and B' are each independently a purine residue or a pyrimidine residue linked through the 9- or 1-position, respectively, provided that compounds disclosed in Table I are excluded. In the instance where B and B' are uracil, attached at the N-1 position to the ribosyl moiety, then the total of m+n may equal 3 or 4 when X is oxygen.The compounds of the present invention are highly selective agonists of the P2Y.sub.2 purinergic receptor, thus, they are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compounds of the present invention are also useful in the treatment of sinusitis and otitis media.Type: GrantFiled: February 10, 1997Date of Patent: November 17, 1998Assignee: Inspire Pharmaceuticals, Inc.Inventors: William Pendergast, Benjamin R. Yerxa, Janet L. Rideout, Suhaib M. Siddiqi
-
Patent number: 5185437Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Also provided are pharmaceutical formulations and processes for the production of the compounds of the invention.Type: GrantFiled: August 31, 1991Date of Patent: February 9, 1993Assignee: Burroughs Wellcome Co.Inventors: George W. Koszalka, Charlene L. Burns, Thomas A. Krenitsky, Janet L. Rideout
-
Patent number: 5153318Abstract: The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.Type: GrantFiled: October 2, 1990Date of Patent: October 6, 1992Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, George A. Freeman, Steven A. Short, Merrick R. Almond, Jon L. Collins
-
Patent number: 5093114Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: November 30, 1990Date of Patent: March 3, 1992Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrmaan, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 5086044Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir.Type: GrantFiled: April 18, 1990Date of Patent: February 4, 1992Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 5068320Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and derivatives thereof. The compounds are useful as antivirals.Type: GrantFiled: October 6, 1989Date of Patent: November 26, 1991Assignee: Burroughs Wellcome Co.Inventors: George W. Koszalka, Charlene L. Burns, Thomas A. Krenitsky, Janet L. Rideout
-
Patent number: 5064946Abstract: Several novel 3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl derivatives of substituted pyrimidinones having antiretroviral, especially anti-AIDS, activity are described.Type: GrantFiled: December 20, 1989Date of Patent: November 12, 1991Assignee: Burroughs Wellcome Co.Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout
-
Patent number: 5041543Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.Type: GrantFiled: September 16, 1988Date of Patent: August 20, 1991Assignee: Burroughs Wellcome Co.Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout
-
Patent number: 4916218Abstract: This invention relates to a new synthetic process for the manufacture of zidovudine from the starting material D-xylose involving:(i) Conversion of D-xylose to a 1-(.beta.-D-xylofuranosyl)thymine derivative;(ii) 2'-Deoxygenation of the thymine derivative; and(iii) 3'-Azidation of the 2'-deoxy compound.Type: GrantFiled: June 9, 1988Date of Patent: April 10, 1990Inventors: Merrick R. Almond, Jeffrey D. Wilson, Janet L. Rideout
-
Patent number: 4874609Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: February 8, 1988Date of Patent: October 17, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4857511Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: February 8, 1988Date of Patent: August 15, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4847244Abstract: Treatments of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 20, 1987Date of Patent: July 11, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4837208Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 20, 1987Date of Patent: June 6, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4833130Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 20, 1987Date of Patent: May 23, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4828838Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 21, 1987Date of Patent: May 9, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4818750Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-dexoythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 20, 1987Date of Patent: April 4, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4818538Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: October 21, 1987Date of Patent: April 4, 1989Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4780453Abstract: Treatment of cats carrying or infected with the Feline Leukemia virus or having antibodies to the Feline leukemia virus is disclosed using the compound 3'-azido''-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: December 23, 1986Date of Patent: October 25, 1988Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
-
Patent number: 4780452Abstract: This invention discloses a group of compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, COOR.sup.4 (R.sup.4 is H or C.sub.1-4 alkyl) or trifluoromethyl; R.sup.2, R.sup.5 and R.sup.6 are the same or different and can be hydrogen, hydroxy, OCOR.sup.7 (wherein R.sup.7 is hydrogen, C.sub.1-4 alkyl, phenyl optionally substituted) or halo; and R.sup.3 is hydrogen, COR.sup.4, C.sub.3-6 cycloalkyl or C.sub.1-4 alkyl or alkenyl; R.sup.2 may also be a phosphate group and pharmaceutically acceptable salts thereof which have been found to have analgesic activity. In addition, these compounds have antiinflammatory, antipyretic, antihypertensive and vasodilatory activity in varying degrees. Some of these compounds also have antiprotozoal and antiviral properties.Type: GrantFiled: September 8, 1986Date of Patent: October 25, 1988Assignee: Burroughs Wellcome Co.Inventors: Thomas A. Krenitsky, Janet L. Rideout, George W. Koszalka